1. Medtech Insight
  2. >>Geography
  3. >>Asia

Thailand Rolls Out IMDRF-Based Risk Classifications For Devices And Diagnostics

 
• By Ashley Yeo

Thailand has opted to align with IMDRF principles on the classification of devices. The change also brings the Thai FDA into line with Asean Medical Device Directive principles.

Thailand

The Thai Food and Drug Administration (FDA) has established a new four-risk class system for classifying medical devices and in vitro diagnostics (IVDs).

The change, published in the Thai Government Gazette on 18 December, at a stroke brings the national regulatory system into...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Asia

India Sets Sights On ‘First-In-World’ Medtech Innovation

 
• By Ashley Yeo

India is transforming its medtech sector from a consumer-importer market into an innovator-exporter industry. But stakeholders are aware of a public-private investment imbalance, In Vivo notes in part three of its APACMed 2025 conference report.

20 New Healthtechs At APAC Showcase: Australis’ Overactive Bladder Patch Scoops Top Award

 
• By Ashley Yeo

The top awards at the annual MedTech Innovator APAC are handed out to an increasingly varied range of products and applications, and the class of 2025 was no exception in its reflection of healthtech’s ever-widening innovator base.

Is 30-Day Response Window In FDA Warning Letter A Mistake Or Shift In Policy?

 
• By Brian Bossetta

Two recent warning letters from the US FDA provide the companies with 30 business days to respond instead of the usual 15. Though not a regulatory requirement, the 15-day time frame has become the standard.

As Medtech Tariffs Loom, AdvaMed Responds With Its Own Plan Emphasizing ‘Reciprocal’ Free Trade

 
• By Brian Bossetta

The US Department of Commerce’s investigation into the national security impact of importing various medical equipment could lead to tariffs on many products. Device industry responds by emphasizing the robustness of domestic production, but also the rigidity of supply and reimbursement agreements.

More from Geography

interview

What Exact-ly Is In Store For Liquid Biopsy?

 
• By Barnaby Pickering

Ahead of Exact Science’s $21bn dollar acquisition by Abbott, Medtech Insight spoke to the company’s chief medical officer, Tomasz Beer, to learn more about the company’s multi-cancer early detection offering, its wider portfolio of products and to hear more about the direction of the field.

LDTs Aimed At Catching Cancers Early Hold Promise In Reducing Late-Stage Diagnoses, Study Shows

 
• By Brian Bossetta

A recent study demonstrates that certain types of blood-based tests that screen for multiple cancers at once have the potential to flip the script on cancer diagnoses, including some of the deadliest types.

How The EU’s Digital Omnibus Package Could Provide Breathing Space For Medtech

 
• By Amanda Maxwell

The European Commission seems to have heeded many of the medtech industry’s points regarding challenges with the implementation of the AI Act within the Digital Omnibus. But the usual EU hurdles must be crossed before the sector will know if these proposals will make it into law.